Earn CME Credits Online

The newest CME presentations are at the top of this page.
Those nearing expiration are nearer the bottom of the page.

Multiple Myeloma: An Update on Current & Emerging Care Options
As with all cancers, early detection and treatment are necessary for optimal patient outcomes. The rapidly evolving nature of multiple myeloma treatment advances, coupled with the disease’s cytogenetic heterogeneity and the ongoing need to manage comorbidities and adverse effects of therapy, magnify the challenge to clinicians of delivering patient-tailored therapy. Thus, medical directors, oncologists, practicing physicians and nurses involved in the care of patients with multiple myeloma stand to benefit from learning how to use emerging treatment data to optimize treatment strategies for patients with newly diagnosed and relapsed or refractory disease.
CME Valid to May 31, 2013

Individualizing First Line and Maintenance Therapy Strategies for Advanced NSCLC
Description: NSCLC is often diagnosed at an advanced stage, and despite progress in early detection and treatment, prognosis is poor. Historically, treatment has included a variety of modalities such as surgery, chemotherapy, and radiotherapy. More recently, therapeutic options for NSCLC have evolved to include targeted agents such as bevacizumab, erlotinib, gemcitabine, docetaxel, pemetrexed, paclitaxel, and cetuximab. The expanding role of the targeted therapies and the concept of tailoring therapies based on clinical and molecular markers are transforming the treatment of NSCLC.
CME Valid to March 31, 2013

Therapy for Advanced Melanoma
Melanoma is the most serious type of skin cancer. It occurs in skins cells called melanocytes, and while it is predominantly found in the skin, it can occur in any area that contains melanocytes. Melanoma will be found in approximately 70,000 people in the United States in 2011 according to the National Cancer Institute. While it is the least common amongst skin cancers, it is by far the most deadly, with 8,800 people expected to die in 2011. In the early stages of melanoma, prognosis is usually good for patients, but when the melanoma becomes metastatic and spreads to other areas of the body, prognosis is especially poor. Fortunately for patients with metastatic melanoma, and the physicians that treat them, significant progress has been made in the treatment of this deadly disease over the past decade, especially in the area of immunotherapies. With a new, breakthrough immunotherapy recently approved for patients with metastatic melanoma, it is critical to educate medical directors, practicing physicians, nurses and other healthcare professionals on the available treatment options and guideline recommendations.
CME Valid to March 31, 2013

Preventing Chemotherapy-Induced Nausea and Vomiting and Improving Quality of Life
Treatment options and combinations for CINV vary depending on the chemotherapeutic agent’s potential for emesis. In acute CINV, recent recommendations from the National Comprehensive Cancer Network (NCCN) suggest that highly and moderately emetogenic chemotherapy may be treated with a combination of a 5-HT3 antagonist (palonosetron, dolasetron, granisetron, or ondansetron) plus dexamethasone with or without aprepitant, while a chemotherapy drug with low emetogenicity may be treated with dexamethasone, metoclopramide, or prochlorperazine. In delayed CINV, recently updated NCCN guidelines have shown that palonsetron is preferred with highly and moderately emetogenic chemotherapy. With the addition of these drugs (whether orally or intravenously) to chemotherapy, research shows that CINV has been prevented in as many as 80% of patients who normally experience nausea and vomiting after treatment. Due to the high success rate of antiemetic medication, patients no longer have to accept nausea, vomiting, and decreased quality of life as an automatic consequence of treating cancer. Because of this and the fact that up to 50% of patients delay or refuse potentially life-saving or life-prolonging chemotherapy treatments, it is extremely important to educate medical directors, nurses, and clinicians on the available and upcoming treatments for CINV.
CME Valid to March 31, 2013

Optimizing Treatment Strategies in the Management of Non-small Cell Lung Cancer (NSCLC)
As non-small-cell lung cancer therapies and treatments continue to both grow and change, it is critical that we provide healthcare professionals across all spectrums updated information about both NSCLC itself and the treatment options that can greatly improve a patient’s quality of life and prognosis. Medical directors, practicing physicians, oncologists, and nurses will learn the optimal use of current therapies in managing this disease, and results from clinical trials that could change the landscape in NSCLC treatment, ultimately helping patients achieve a greater quality of life and improved clinical outcomes.
CME Valid to December 31, 2012

Emerging Trends and Strategies In The Treatment of Breast Cancer
Breast Cancer is the most common cancer found in women, regardless of race or ethnicity. According to the National Cancer Institute, an estimated 192,370 new cases of invasive breast cancer are expected to be diagnosed in women in the United States during 2010, along with 67,770 new cases of non-invasive breast cancer. The incidence in women in the United States is 1 in 8 (about 13 percent). About 40,170 women in the U.S. died from breast cancer last year, though death rates have been steadily decreasing over the past 20 years due to new and ever improving treatment options. In fact, 96 percent of women who are diagnosed and treated for breast cancer early will be cancer-free after five years, which underscores the need for early and aggressive treatment.

Effective and timely treatment of breast cancer can greatly improve both survival rates and quality of life. With the advancement and complexity of different treatment options, clinicians are being challenged to quickly diagnose breast cancer and it's corresponding stage, and provide the correct treatment options that are available to patients. Evaluating all of the treatment options is critical for newly diagnosed patients, and patients facing a metastasis, which is why it is imperative to inform Medical Directors, Case Managers, and other healthcare personnel about the newest advances in treatment and the best ways to navigate those treatment options.
CME Valid to October 31, 2012

Decision Making in Advanced Breast Cancer
Surgery, chemotherapy, radiation therapy, hormonal therapy, and targeted therapies are some of the options that oncologists have available at their disposal. Depending on the patient's breast cancer stage, and other factors such as age and health, they can pick the most appropriate option from this assortment of treatments. With so many options available for different subtypes of patients, clinicians must stay up to date on the most recent advances in breast cancer therapy. That is why it is imperative to educate medical directors, physicians, nurses, and other healthcare personnel about the newest advances in treatment for metastatic breast cancer.
CME Valid to September 30, 2012

Chemotherapy Induced Nausea and Vomiting (CINV): Perceptions, Mechanisms and Treatment Guidelines
Patients no longer have to accept nausea, vomiting, and decreased quality of life as an automatic consequence of treating cancer. Due to the high success rate of antiemetic medication and the fact that up to 50% of patients delay or refuse potentially life-saving chemotherapy treatments, it is extremely important to educate medical directors, nurses, and clinicians on the available and upcoming treatments for CINV. Acquiring this knowledge to pass onto chemotherapy patients will not only help to improve patient compliance, but will also ultimately improve patient outcomes for cancer patients enduring chemotherapy.
CME Valid to August 31, 2012

Non-Small Cell Lung Cancer (NSCLC): Current and Novel Treatment Strategies
Guidelines from the National Comprehensive Cancer Network (NCCN) have recently been updated to incorporate a section on maintenance therapy and revised staging system with regards to NSCLC. This updated information is critical for medical directors, oncologists, and nurses as they all must stay up to date on both the disease and the different and ever-changing treatment options and methods in NSCLC. As cancer therapies and treatments continue to both grow and change, it is critical that we provide healthcare professionals across all spectrums updated information about both NSCLC itself and the treatment options involved that can greatly improve a patient’s quality of life and prognosis. Medical directors, oncologists, and nurses will also be able to educate both their staff and colleagues in direct patient care and ultimately increase organizational quality as well as improve outcomes in the NSCLC patient population.
CME Valid to August 31, 2012

Management of Venous Thromboembolism (VTE) in Cancer Patients
There have been many breakthroughs in the treatment and prophylaxis of VTE in cancer patients. Many options are available for oncologists and providers to use in their patient populations. These agents include low-molecular weight heparin (LMWH), unfractionated heparin (UFH), and warfarin among others. Additionally, there are options that are currently in clinical trials that could be of great benefit to cancer patients. Both the National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) have come out with recent guidelines regarding the treatment of cancer patients with VTE. It is critical to inform medical directors, clinicians, oncologists and nurses about what these guidelines recommend and what treatment options are currently available for cancer patients.

Despite having guidelines that provide specific recommendations, studies have shown that many cancer patients receive either no or inappropriate thrombo-prophylaxis. Educational interventions that promote these evidence-based guidelines and appropriate use of available therapies can help in the prevention of VTE and its associated complications. Therefore, this activity has been planned in accordance with the need to provide medical directors, clinicians, oncologists and nurses with education to improve appropriate thrombo-prophylaxis and treatment in their patient populations.
CME Valid to August 31, 2012

Non Small Cell Lung Cancer State of Art
Lung cancer is the second most common cancer in both men and women, according to the American Cancer Society. It accounts for about 15% of all new cancers, and during 2011, it is expected that there will be about 219,440 new cases of lung cancer. Non small-cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancer cases. Lung cancer is by far the leading cause of cancer death among both men and women, and there will be an estimated 159,000 deaths from lung cancer in 2010, accounting for around 29% of all cancer deaths. More people die of lung cancer than of colon, breast, and prostate cancers combined. However, advances in our knowledge of cancer cell biology have led to the development of specific molecular-targeted therapeutic agents, offering oncologists more treatment options in the fight against NSCLC.
CME Valid to July 31, 2012

Treatment Options in Metastatic Breast Cancer
Effective and timely treatment of metastatic breast cancer can greatly improve both survival rates and quality of life. With the advancement and complexity of different treatment options, clinicians are being challenged to quickly diagnose breast cancer and its corresponding stage, and provide the correct treatment options that are available to patients. Tremendous strides are made regularly in the treatment of both hormone-positive and hormone-negative disease, as well as for patients with specific tumor subtypes (eg, HER2 over expressing tumors), posing a challenge to the clinician who must stay up to date on the most recent advances in breast cancer therapy.
CME Valid to July 25, 2012

Considering Treatment Options in Advanced Non-Small Cell Lung Cancer
Lung cancer is the second most common cancer in both men and women, according to the American Cancer Society. It accounts for about 15% of all new cancers, and during 2010, it is expected that there will be about 219,440 new cases of lung cancer. Non small-cell lung cancer (NSCLC) accounts for approximately 15% of all lung cancer cases. Lung cancer is by far the leading cause of cancer death among both men and women, and there will be an estimated 159,000 deaths from lung cancer in 2010, accounting for around 29% of all cancer deaths. More people die of lung cancer than of colon, breast, and prostate cancers combined. However, advances in our knowledge of cancer cell biology have led to the development of specific molecular-targeted therapeutic agents, offering oncologists more treatment options in the fight against NSCLC.
CME Valid to July 25, 2012

What’s New in the Pharmacological Management of Prostate Cancer
Early detection and timely treatment of prostate cancer can greatly improve both survival rates and quality of life. With the advancement and complexity of different treatment options, clinicians are being challenged to quickly diagnose prostate cancer, it's corresponding stage, and provide the correct treatment options that are available to patients.

Treatments are evolving so quickly for prostate cancer patients, and it is becoming more and more difficult for clinicians, medical directors and nurses to keep up with the latest options that might be available for their patient populations. Continuing education about prostate cancer is key in keeping these healthcare professionals up to date on both agents that are available now, and those that will become available in the near future.
CME Valid to July 25, 2012

Improving Quality of Life for Cancer Patients: Treating CINV
Patients no longer have to accept nausea, vomiting, and decreased quality of life as an automatic consequence of treating cancer. Due to the high success rate of antiemetic medication and the fact that up to 50% of patient’s delay or refuse potentially life-saving chemotherapy treatments, it is extremely important to educate medical directors, nurses, and clinicians on the available and upcoming treatments for CINV. Acquiring this knowledge to pass onto chemotherapy patients will not only help to improve patient compliance, but will also ultimately improve patient outcomes for cancer patients enduring chemotherapy.
CME Valid to June 1, 2012

Multiple Myeloma: An Update on Diagnostic and Treatment Strategies
Multiple Myeloma (MM) accounts for 10% of hematologic malignancies. In 2009, it is estimated that MM was responsible for 11,000 new deaths and 20,580 new cases. Multiple myeloma is a systemic malignancy of plasma cells that is highly treatable but rarely curable. It is potentially curable when it presents as a solitary plasmacytoma of bone or as an extramedullary plasmacytoma. The median survival in the prechemotherapy era was about 7 months. After the introduction of chemotherapy, prognosis improved significantly with a median survival of 24 months to 30 months and a 10-year survival of 3%. Even further improvements in prognosis have occurred because of the introduction of newer therapies, including novel agents such as bortezomib and lenalidomide. As with all cancers, early detection and treatment are necessary for optimal patient outcomes. Medical directors, practicing physicians and physician executives feel that they need to be updated through continuing education on Multiple Myeloma and stay informed on the diagnosis and treatments to appropriately manage their population.
CME Valid to June 30, 2012

Business/Practice Management	Preventive Health & Lifestyle Medicine	Chronic Illness
Behavioral Health	Oncology	Genomics, Biotech & Emerging Medical Technologies